Oral Sleep Apnea - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The oral sleep apnea market size is expected to increase from USD 0.78 billion in 2025 to USD 0.88 billion in 2026 and reach USD 1.72 billion by 2031, growing at a CAGR of 14.28% over 2026-2031. This report is Segmented by Device Type (Mandibular Advancement Devices, Tongue Stabilising Devices, Hybrid/Combination Oral Appliances, Custom 3-D-Printed Devices), End User (Hospitals, Dental Clinics & Sleep Dentistry Centres, Homecare Settings), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Oral Sleep Apnea Market Trends and Insights

Rising Prevalence of Obstructive Sleep Apnea

The global prevalence of OSA reached 936 million adults in 2024, and 425 million of them already have moderate-to-severe disease, which elevates the oral sleep apnea market’s addressable base. China alone hosts 176 million patients, but 90% remain undiagnosed because sleep-laboratory capacity is concentrated in tier-1 cities. Japan’s population over 65 exhibits OSA prevalence above 50%, pushing insurers to reimburse early treatment that averts cardiovascular events. This epidemiologic burden is amplifying political pressure for low-cost screening, catalyzing demand for digitally fabricated devices that can be shipped nationwide within days. Manufacturers positioning oral appliances as preventive rather than reactive fit neatly into public-health agendas that now prize cost avoidance over episodic interventions.

Increasing Diagnosis Via Home-Sleep Testing

The FDA cleared a succession of home sleep apnea tests (HSATs) - SANSA’s wearable patch, Huxley’s ring, and Withings’ ScanWatch 2 throughout 2024, enabling physicians to diagnose OSA without polysomnography. The United Kingdom’s December 2024 NICE guidance endorsed home testing, saving GBP 200-400 per patient and shortening diagnostic wait times from weeks to days. Faster diagnosis speeds oral appliance prescriptions, as patients bypass congested sleep centers and book same-week tele-dentistry appointments. Tele-enabled models also democratize access for rural populations, where courier-shipped devices paired with video titration replace multiple in-clinic visits. Manufacturers with direct-to-consumer logistics and digital impression kits, therefore, capture incremental volume without expanding brick-and-mortar footprints.

Limited Long-Term Efficacy Vs CPAP

Meta-analyses show CPAP cuts AHI 25-30 events per hour in severe OSA, while MADs cause salivation, TMJ pain, or occlusal changes. Discontinuation is more common in bruxism or reduced protrusion ranges (< 6 mm). Multi-visit titration costs USD 100-200 per appointment, where insurance is patchy, accelerating dropout. Unlike CPAP, oral edema has an average of 10-15, leaving residual risk for cardiovascular disease. Although higher nightly adherence narrows the gap, payers still judge therapy on per-night efficacy. Germany and the Netherlands now require 5-year outcome data before broadening reimbursement, evidence that the appliance segment has yet to provide. This efficacy ceiling caps the penetration of the oral sleep apnea market in high-severity cohorts.

Other drivers and restraints analyzed in the detailed report include:

• Favourable Reimbursement for Oral Appliances
• Patient Preference for Non-Invasive CPAP Alternatives
• Poor Device Adherence & Comfort Issues

Segment Analysis

Mandibular advancement devices captured 66.02% of 2025 revenue, reflecting robust reimbursement and extensive clinical validation. Custom 3-D-printed MADs priced at USD 1,500-2,500 dominate Medicare and German SHI channels, while semi-custom boil-and-bite variants at USD 300-800 appeal to cash-pay buyers in Latin America and Southeast Asia. Tongue stabilizing devices will grow at 15.06% CAGR to 2031, propelled by edentulous and limited-protrusion patients unsuited for MADs. Hybrid concepts such as Oventus Medical’s O2Vent add an airway channel that circumvents nasal obstruction, carving a small but strategic niche.

The digitally printed appliances sub-segment is the fastest mover. GoodSleepCo’s hushd Pro Avera and Airway Management’s Nylon flexTAP received clearances in 2024-2025, proving nylon’s overnight biocompatibility and supporting latticed designs impossible with thermoforming. Device files are delivered instantly to contract printers in India, Mexico, and Eastern Europe, compressing lead times and enabling same-week patient delivery. Players that straddle premium custom and low-cost semi-custom lines, such as SomnoMed’s Avant and Classic series, balance margin against volume but must orchestrate divergent supply chains. Overall, this mix of high-value and value-engineered offerings positions the oral sleep apnea market to address pay-as-you-go buyers without ceding premium reimbursements.

Complete Report Scope:

• By Device Type
  • Mandibular Advancement Devices (MADs)
  • Tongue Stabilising Devices (TSDs)
  • Hybrid / Combination Oral Appliances
  • Custom 3-D-printed Devices
• By End User
  • Hospitals
  • Dental Clinics & Sleep Dentistry Centres
  • Homecare Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.18% of 2025 revenue, driven by Medicare reimbursement and a network of 2,000 AADSM Diplomates. The United States counts about 30 million adults with moderate-to-severe OSA, but only 6 million receive treatment, leaving a penetration gap the oral sleep apnea market can mine as HSAT expands. Canada’s patchwork provincial coverage ranges from CAD 800 reimbursements in Ontario to near-zero support in British Columbia, encouraging tiered pricing for devices. Mexico’s mostly cash-pay environment opens opportunities for semi-custom devices at USD 400-1,200.

Europe’s growth is steady but hampered by reimbursement heterogeneity. Germany reimburses under specific ICD codes yet imposes co-pays of EUR 50-150, while the United Kingdom’s NHS covers only limited cases, pushing most patients to pay GBP 800-1,500 out of pocket. France reimburses 60% of the tariff, but administrative delays can reach 8 weeks. Italy and Spain suffer from practitioner scarcity, leaving latent demand untapped. However, NICE’s 2024 home-testing endorsement should shorten diagnostic pipelines and prompt higher market penetration for oral sleep apnea in the United Kingdom.

Asia-Pacific is the growth engine, advancing at 17.27% CAGR through 2031. China’s 176 million patients drive volume for CNY 1,500-3,000 semi-custom devices, while NMPA fast-tracks imported appliances from SomnoMed and ProSomnus. Japan’s aging society and universal insurance create premium reimbursement, yet PMDA’s stringent trials delay launches 12-18 months. India remains nascent, with fewer than 200 dental-sleep practitioners, but rising corporate wellness programs and urban awareness are seeding future demand. Australia serves as an early-adopter test bed thanks to TGA’s smooth approvals and compulsory health coverage.

Middle East & Africa and South America trail behind because of scarce sleep centers and patchy insurance coverage. GCC nations are building specialty clinics, but adoption is limited to expatriate-dominated private sectors. Brazil and Argentina contend with economic volatility, nudging buyers toward lower-priced devices even as ANVISA approvals in 2024-2025 ease import barriers.

List of Companies Covered in this Report:

• Airway Management Inc (TAP)
• Allengers Medical Systems Ltd.
• Apnea Sciences Corp
• Dynaflex
• Erkodent GmbH
• Henry Schein
• Keller Laboratories
• Oventus Medical
• Panthera Dental
• ProSomnus Sleep Technologies
• Resmed
• Scheu-Dental GmbH
• SomnoMed Ltd
• Vivos Therapeutics
• Whole You (Mitsui Chemicals)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support